AngioSoma Strengthens IP Position With New Patent Filing

OmniCath™ II Patent Filing Showcases Product Effectiveness

Houston, TX, Oct. 16, 2018 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — AngioSoma (SOAN), a leading pharmaceutical research and development company, announces the filing of new patent application number 62/549.262 covering the OmniCath® II, an Atherectomy device. The new patent begins with the original base patent, the company’s patent of the original OmniCath® I atherectomy catheter, U.S. Patent 5,728,129, that expired in June of this year.

Improvements included in the new patent is the inclusion of a completely detachable and disposable catheter shaft, driveline, cutter, and angioplasty balloon from motor assembly preventing cross contamination of infections such as MRSA while allowing reuse of its lithium battery powered motor.  These new features maximize patient safety, effectiveness and sustainability.

“From the outset, we recognized the importance of developing and then protecting our technologies,” said Alex Blankenship, president of AngioSoma. “As a one of the forerunners in this space, AngioSoma has demonstrated our continued commitment and leadership on the space. Having our innovative approach to heart and health treatments recognized by the patent office makes all of us very proud.”

Atherectomy devices help in plaque removal, particularly calcified plaque, by physically drilling, pulverizing or shaving it. This technique is a popular substitute for stents and angioplasty treatments. In stents and angioplasty, the deposited plaque is pushed inside the blood vessel, however in atherectomy the plaque is removed by using surgical methods. This technique has advantages over other methods by providing increased wound healing rate.

For more information about OmniCath® II, please visit:


AngioSoma, Inc. (https://, a Nevada corporation based in Houston, Texas, is dedicated to improving the mental and physical wellbeing of men and women. To accomplish that purpose, we are launching a line of supplements under our Somaceuticals™ common identity. Our supplements cover three industry segments: nutraceuticals, cosmeceuticals, and pharmaceuticals.


Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words “believes,” “expects,” “anticipate” or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements.